Published in Malar J on April 14, 2014
Salinomycin and other ionophores as a new class of antimalarial drugs with transmission-blocking activity. Antimicrob Agents Chemother (2015) 0.82
Predicting Mouse Liver Microsomal Stability with "Pruned" Machine Learning Models and Public Data. Pharm Res (2015) 0.81
Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles. ACS Cent Sci (2016) 0.80
Implications of the small number of distinct ligand binding pockets in proteins for drug discovery, evolution and biochemical function. Bioorg Med Chem Lett (2015) 0.76
Assessment of SYBR green I dye-based fluorescence assay for screening antimalarial activity of cationic peptides and DNA intercalating agents. Antimicrob Agents Chemother (2015) 0.75
Plasmodium falciparum in vitro continuous culture conditions: A comparison of parasite susceptibility and tolerance to anti-malarial drugs throughout the asexual intra-erythrocytic life cycle. Int J Parasitol Drugs Drug Resist (2017) 0.75
Human malaria parasites in continuous culture. Science (1976) 59.70
Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother (1979) 17.49
Thousands of chemical starting points for antimalarial lead identification. Nature (2010) 8.28
Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother (2004) 7.51
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Malaria. Did they really say ... eradication? Science (2007) 5.04
New medicines to improve control and contribute to the eradication of malaria. Nat Rev Drug Discov (2009) 4.00
A research agenda for malaria eradication: drugs. PLoS Med (2011) 3.90
Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. Antimicrob Agents Chemother (2004) 3.77
Antiretrovirals as antimalarial agents. J Infect Dis (2004) 3.60
A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol (2006) 2.72
Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol (2009) 2.61
Artemisinin resistance--the clock is ticking. Lancet (2010) 2.22
Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des (2006) 2.10
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis (2010) 2.08
Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation. Exp Parasitol (1983) 2.03
A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS One (2008) 1.92
Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis (2009) 1.74
Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob Agents Chemother (2009) 1.73
Quinolone-3-diarylethers: a new class of antimalarial drug. Sci Transl Med (2013) 1.60
The global pipeline of new medicines for the control and elimination of malaria. Malar J (2012) 1.57
Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol (2012) 1.53
A high-throughput screen targeting malaria transmission stages opens new avenues for drug development. J Infect Dis (2011) 1.49
Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs (2012) 1.44
Quantitative measurement of Plasmodium-infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO-16 fluorescence. Cytometry A (2009) 1.41
Effect of cyclosporine on parasitemia and survival of Plasmodium berghei infected mice. Biochem Biophys Res Commun (2008) 1.41
Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J (2006) 1.37
Drug repositioning for orphan diseases. Brief Bioinform (2011) 1.37
Protein kinases as targets for anti-parasitic chemotherapy. Biochim Biophys Acta (2004) 1.36
Global phenotypic screening for antimalarials. Chem Biol (2012) 1.35
Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol (2011) 1.29
Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening. Am J Trop Med Hyg (2012) 1.28
Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. PLoS One (2008) 1.22
Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J Infect Dis (2012) 1.18
A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res (2011) 1.09
Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol (1999) 1.09
The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol (2011) 1.09
Antimalarials in the treatment of schistosomiasis. Curr Pharm Des (2012) 1.07
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B. BMC Clin Pharmacol (2007) 1.05
The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice. Z Parasitenkd (1983) 1.01
Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. Proc Natl Acad Sci U S A (2010) 1.00
New anti-tuberculosis agents amongst known drugs. Tuberculosis (Edinb) (2009) 0.97
The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. PLoS One (2012) 0.95
Drug repositioning in the treatment of malaria and TB. Future Med Chem (2011) 0.94
Road towards new antimalarials - overview of the strategies and their chemical progress. Curr Med Chem (2011) 0.93
Anticancer agents against malaria: time to revisit? Trends Parasitol (2010) 0.91
Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Trop Med Int Health (2010) 0.90
Methotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax. J Infect Dis (2010) 0.90
Haemolysis risk in methylene blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs. Pharmacoepidemiol Drug Saf (2012) 0.84
The potential use of methotrexate in the treatment of falciparum malaria: in vitro assays against sensitive and multidrug-resistant falciparum strains. Jpn J Infect Dis (2008) 0.84
Mammalian interphase cdks: dispensable master regulators of the cell cycle. Genes Cancer (2012) 0.82
Fast mouse PK (Fast PK): a rapid screening method to increase pharmacokinetic throughput in pre-clinical drug discovery. Eur J Pharm Sci (2012) 0.81
Targeting protein kinases in the malaria parasite: update of an antimalarial drug target. Curr Top Med Chem (2012) 0.81
A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. Malar J (2011) 0.81
APT drug R&D: the right active ingredient in the right presentation for the right therapeutic use. Nat Rev Drug Discov (2009) 0.81
Artemisinin derivatives: a patent review (2006 - present). Expert Opin Ther Pat (2012) 0.79
The metabolism of platelet-activating factor in severe and cerebral malaria. J Infect (1995) 0.78
Methotrexate and aminopterin lack in vivo antimalarial activity against murine malaria species. Exp Parasitol (2009) 0.76
Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell (2004) 5.95
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Inactivation of the p53 pathway in retinoblastoma. Nature (2006) 4.57
Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. Proc Natl Acad Sci U S A (2006) 3.90
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science (2009) 3.39
Metabolic oxidation regulates embryonic stem cell differentiation. Nat Chem Biol (2010) 3.06
Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab (2002) 2.69
A molecular fingerprint for medulloblastoma. Cancer Res (2003) 2.66
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci U S A (2011) 2.58
Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem (2003) 2.25
Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMedChem (2013) 2.20
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother (2006) 2.14
Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des (2006) 2.10
Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology (2002) 2.09
Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2004) 1.99
A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci U S A (2007) 1.97
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem (2011) 1.94
Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem (2010) 1.85
Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol (2005) 1.82
Reporting data from high-throughput screening of small-molecule libraries. Nat Chem Biol (2007) 1.79
The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem (2009) 1.79
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell (2011) 1.78
Moving beyond the keg party: a daily process study of college student drinking motivations. Psychol Addict Behav (2005) 1.73
An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res (2007) 1.73
Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob Agents Chemother (2009) 1.73
The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem (2004) 1.66
Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology (2003) 1.60
ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res (2002) 1.58
Novel small-molecule inhibitors of RNA polymerase III. Eukaryot Cell (2003) 1.56
Ligand-selective inhibition of the interaction of steroid receptor coactivators and estrogen receptor isoforms. Chem Biol (2004) 1.53
The interdependence between screening methods and screening libraries. Curr Opin Chem Biol (2007) 1.48
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) (2012) 1.47
Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model. J Biol Chem (2010) 1.46
Scaffold composition and biological relevance of screening libraries. Nat Chem Biol (2007) 1.45
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob Agents Chemother (2010) 1.44
Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Am J Trop Med Hyg (2009) 1.43
HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol (2010) 1.43
Identification of inhibitors of Plasmodium falciparum gametocyte development. Malar J (2013) 1.43
Quantitative measurement of Plasmodium-infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO-16 fluorescence. Cytometry A (2009) 1.41
Natural products, stylissadines A and B, specific antagonists of the P2X7 receptor, an important inflammatory target. J Org Chem (2007) 1.41
3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem (2012) 1.40
Valuing nature-based recreation in public natural areas of the Apalachicola River region, Florida. J Environ Manage (2007) 1.39
Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci U S A (2009) 1.37
Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. PLoS Negl Trop Dis (2012) 1.36
Global phenotypic screening for antimalarials. Chem Biol (2012) 1.35
Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J Med Chem (2008) 1.32
Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J Biol Chem (2005) 1.32
Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors. J Comb Chem (2006) 1.32
Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening. Am J Trop Med Hyg (2012) 1.28
Improvement of detection specificity of Plasmodium-infected murine erythrocytes by flow cytometry using autofluorescence and YOYO-1. Cytometry A (2005) 1.27
Parallel synthesis and antimalarial screening of a 4-aminoquinoline library. J Comb Chem (2004) 1.23
Inhibition of a viral enzyme by a small-molecule dimer disruptor. Nat Chem Biol (2009) 1.21
Identification of MMV malaria box inhibitors of plasmodium falciparum early-stage gametocytes using a luciferase-based high-throughput assay. Antimicrob Agents Chemother (2013) 1.18
Challenges in antimalarial drug discovery. Future Med Chem (2011) 1.17
Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase. Expert Opin Drug Discov (2009) 1.16
Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA. J Med Chem (2014) 1.15
Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. Mol Endocrinol (2009) 1.14
Role of electrostatic interactions in PDZ domain ligand recognition. Biochemistry (2003) 1.13
Isotopically labeled crosslinking reagents: resolution of mass degeneracy in the identification of crosslinked peptides. Bioorg Med Chem Lett (2003) 1.12
Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorg Med Chem Lett (2005) 1.11
Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor. Mol Endocrinol (2007) 1.10
Activity of piperaquine and other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant blood-stages of Plasmodium falciparum. Role of beta-haematin inhibition and drug concentration in vacuolar water- and lipid-phases. Biochem Pharmacol (2007) 1.10
Quantification of the vitamin D receptor-coregulator interaction. Biochemistry (2009) 1.10
Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. J Med Chem (2011) 1.09
Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells. Toxicol Appl Pharmacol (2009) 1.09
A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding. Sci STKE (2006) 1.08
Quantitative proteomics of the thyroid hormone receptor-coregulator interactions. J Biol Chem (2004) 1.06
An automated approach to efficiently reformat a large collection of compounds. Curr Chem Genomics (2011) 1.06
Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem (2012) 1.05
Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res (2007) 1.05
The response of fenestrations, actin, and caveolin-1 to vascular endothelial growth factor in SK Hep1 cells. Am J Physiol Gastrointest Liver Physiol (2008) 1.05
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother (2007) 1.05
Eimeria tenella sporozoites and merozoites differentially express glycosylphosphatidylinositol-anchored variant surface proteins. Mol Biochem Parasitol (2004) 1.03
Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. J Biol Chem (2012) 1.03
Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg Med Chem Lett (2008) 1.02
Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign. PLoS Negl Trop Dis (2012) 1.02
Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J Am Chem Soc (2003) 1.02
Synthesis and testing of a focused phenothiazine library for binding to HIV-1 TAR RNA. Chem Biol (2006) 1.01
An alpha-helical peptidomimetic inhibitor of the HIV-1 Rev-RRE interaction. J Am Chem Soc (2006) 1.00
Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1. Future Med Chem (2012) 1.00
A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy persons. Am J Trop Med Hyg (2010) 0.99
Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities. Bioorg Med Chem Lett (2005) 0.99
Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa. J Med Chem (2008) 0.99
Thiaplakortones A-D: antimalarial thiazine alkaloids from the Australian marine sponge Plakortis lita. J Org Chem (2013) 0.98
Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models. J Med Chem (2010) 0.98
Antitrypanosomal cyclic polyketide peroxides from the Australian marine sponge Plakortis sp. J Nat Prod (2010) 0.98
Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem (2009) 0.98
A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Parasit Vectors (2009) 0.97
Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. J Med Chem (2013) 0.97
Incorporation of an intramolecular hydrogen-bonding motif in the side chain of 4-aminoquinolines enhances activity against drug-resistant P. falciparum. J Med Chem (2006) 0.96